Accessibility Tools
Book Now

Thank you for choosing TeleSlim Clinic in Illinois!

We accept cash-pay patients in Illinois — no insurance hassles.

Choose an option below to get started.

X
Close

Tirzepatide (Zepbound) for Weight Loss in Illinois

Tirzepatide is a once-weekly medication that works on two gut-hormone pathways, GIP and GLP-1. Zepbound is the tirzepatide brand approved for weight management. This guide summarizes the FDA label.

Important safety information. This page is general education, not medical advice. Only a licensed clinician who knows your history can decide whether a medication is right for you. Do not start, stop or change a prescription without talking to your clinician. If you have severe abdominal pain, trouble breathing, swelling of the face or throat, or thoughts of harming yourself, seek emergency care or call 988.

Book your free visit →

What It Is

Zepbound is a weekly injection that reduces appetite and food intake by activating both GIP and GLP-1 receptors.

FDA-Approved Uses

Zepbound is approved, with diet and exercise, for long-term weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity.

How It Is Taken

Dosing starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps every 4 weeks as tolerated. Maintenance doses are 5, 10 or 15 mg.

What to Expect

In the SURMOUNT-1 trial, adults on the 15 mg dose lost an average of about 21% of body weight over 72 weeks, compared with about 3% on placebo. Lower doses produced less weight loss, and results vary.

Common Side Effects

Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion and injection-site reactions.

Serious Warnings

The label carries a boxed warning for thyroid C-cell tumors seen in animals; it is not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Other warnings include pancreatitis, gallbladder disease, dehydration and kidney injury, low blood sugar with insulin or sulfonylureas, diabetic retinopathy changes, mood changes, and aspiration risk during anesthesia. Tirzepatide can make oral birth control less effective, so a non-oral or added barrier method is advised for 4 weeks after starting and after each dose increase.

Frequently Asked Questions

Is Zepbound the same as Mounjaro?

Both contain tirzepatide. Zepbound is approved for weight management and sleep apnea; Mounjaro is approved for type 2 diabetes.

How is tirzepatide different from semaglutide?

Tirzepatide acts on two hormone pathways; semaglutide acts on one. Your clinician can help compare them for your situation.

Does it affect birth control?

It can reduce the effectiveness of oral birth control pills. Ask your clinician about backup methods.

How TeleSlim Clinic Can Help

A TeleSlim Clinic physician can review your health history and goals by secure video visit and discuss whether prescription weight loss treatment is appropriate for you. Prescribing is always at the clinician's discretion, and not every medication is right for every person. See our Cost & Insurance guides and Illinois locations.

Cost & Insurance guides

TeleSlim Clinic visits are self-pay, and we do not bill insurance for our own services. We do handle prior authorization for your medication, provide a superbill you can submit to your insurance for possible reimbursement, and send your medication and lab orders to the pharmacy or lab you choose, where your insurance can be used. We do not see patients with Medicare.

More in This Library

Start Your Weight Loss Journey

Free visit available — book your free visit.

If you are considering bariatric surgery, learn about surgical options with Dr. Jihad Kudsi at DoctorKudsi.com (https://www.doctorkudsi.com).

Sources: FDA prescribing information for Zepbound (tirzepatide); SURMOUNT-1 trial, New England Journal of Medicine 2022.

This page is general information, not medical advice. Prescribing information changes; confirm current details with your clinician or pharmacist. Last updated: October 7, 2026.